RSS FLASCO

  • Judy Nicholson Kidney Cancer Foundation: Kidney Cancer Conversations May 25, 2020
  • FDA approves ripretinib for advanced gastrointestinal stromal tumor May 20, 2020
    On May 15, 2020, the Food and Drug Administration approved ripretinib (QINLOCK™, Deciphera Pharmaceuticals, LLC.), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Efficacy was evaluated in INVICTUS (NCT03353753), an international, multi-center, randomized (2:1), double-blind, placebo-controlled trial in 129 patients with...
  • FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer May 20, 2020
    On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA®, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Efficacy was investigated in TRITON2 (NCT02952534), an ongoing, multi-center, single arm clinical trial...
  • FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%) May 20, 2020
    On May 15, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO®, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY®, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma...
  • FDA grants accelerated approval to pomalidomide for Kaposi sarcoma May 20, 2020
    From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the...
  • Now FDA-approved: QINLOCK™ (ripretinib) May 20, 2020
  • FCS patients report high satisfaction with care during Covid-19 pandemic May 20, 2020
    Cancer Patients Report High Satisfaction with Care During COVID-19 Pandemic Florida Cancer Specialists & Research Institute establishes protocols to protect patients with minimal disruption Fort Myers, Fla., May 19, 2020 —— Despite the many challenges of the current health care crisis, patients of  Florida Cancer Specialists & Research Institute (FCS) report high satisfaction with the oncology provider’s response...
  • FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer May 20, 2020
    On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Today, the FDA also approved FoundationOne® CDx (Foundation Medicine, Inc.)...
  • New name for Takeda Oncology patient support program May 20, 2020
    Takeda Oncology has changed the name of their patient support program from Takeda Oncology 1Point to Takeda Oncology Here2Assist™ effective May 18, 2020. Please note that only the name is changing. Patients and providers will continue to have the same high level of comprehensive, personalized support. Please review the attached information for important details.
  • FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression May 19, 2020
    On May 18, 2020, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of...